Science.csu.edu.au

Faculty of Science
Prohibited and
Notifiable Carcinogens
Procedure
TRIM file number
Faculty Science Document
Short description
Procedure outlines how prohibited and notifiable carcinogens are managed appropriately. Relevant to
CSU staff, students and researchers Authority
This Procedure has been approved by [Dean, Faculty of Science] under the Governance (Policy and Procedures) Rule 2005 of the Council and sections 20 and 32 of the CSU Act. Responsible officer
Manager, University Laboratories Responsible office
Faculty of Science, Office Date introduced
Date(s) modified
Next scheduled review date
Related University documents
CSU Occupational Health and Safety Policy CSU Risk Management Policy CSU Privacy Management Plan FSc Risk Assessment Procedure Related legislation
OH &S Act 2000 and Regulation 2001, Privacy Act 1988, Privacy and Personal Information Protection Act 1998 (NSW) National Model Regulations for the Control of Scheduled Carcinogenic Substances [NOHSC:1011(1995)] Control of Scheduled Carcinogenic Substances [NOHSC:2014(1995)] NCoP Approved Criteria for Classifying Hazardous Substances [NOHSC: 1108] Key words
Procedure, Workcover, carcinogen, prohibited, notifiable, chemical, substance Prohibited and Notifiable Carcinogens Procedure Version 1.0 Effective 08/2011 In accordance with the CSU Occupational Health and Safety Policy, the CSU Risk Management Policy, the Occupational Health and Safety Act 2000 and the NSW Occupational Health and Safety Regulations 2001 the Faculty of Science (FSc) shall provide a safe and healthy environment for staff, students, visitors and contractors. Central to achieving this is the staff, students, visitors and contractors understanding their duty of care responsibilities and the specialised risk associated with the FSc Facilities. Prohibited and notifiable carcinogens are a specialised risk. This procedure ensures all prohibited and notifiable carcinogens are managed appropriately. All staff who intend to purchase prohibited and notifiable carcinogens (Appendix PROCEDURE
3.1

Research
Consult the Workcover website: Risk assessment
Complete an FSc risk assessment (see Risk Assessment Procedure). Some considerations specific to prohibited and notifiable carcinogens include: Eliminate if possible:
• is the use of a carcinogen essential or can it be eliminated • can an alternative procedure be adopted to reduce exposure • can an alternative substances be used Minimise if elimination is not possible
• aim to minimise the use of the carcinogen • minimise the quantity for purchase • include waste disposal of the carcinogen or its by-products in the risk Note - written approval and notification for intended acquisition and use of
prohibited and notifiable carcinogens must be obtained from:
• The Facility Manager
• Head of School
• Manager, University Laboratories (or delegate)
Notification of approval and intended use shall also be sent to:
• Manager, Occupational Health and Safety Prohibited and Notifiable Carcinogens Procedure Version 1.0 Effective 08/2011 Notify Workcover
3.3.1 Initial application
The Authorised Person (specified on the risk assessment) must apply to Workcover in writing at least 60 days in advance with information for each substance and for each location at which it will be used. The carcinogenic is available on the Workcover website and the following information will be required: • name of substance • quantity or proportion in product or preparation • nature of the product or preparation (e.g. solid, liquid) • estimated annual quantity of product or preparation required or used • details of proposed use (e.g. manufacturing, therapeutic, research) supplier declaration • complete a risk assessment or the need to review a Risk Assessment 3.3.2 Hierarchy of Controls
Further documentation may be required, ensure consideration has been given to: • training and induction • competence of persons handling the carcinogen • engineering controls • administrative controls particularly those to limit exposure • monitoring and health surveillance • risk register • standard operating procedure of all aspects of handling the carcinogen • the labelling, storage and containment of the carcinogen • waste disposal procedures • record keeping in line with legislative requirements 3.3.3 Ongoing Reporting
The written application for working with notifiable and prohibited carcinogens to Workcover must be resubmitted by the Authorised Person if or when the following occurs: • change of location of work with a carcinogenic substance at a work site (i.e. each laboratory) • when a risk assessment has been reviewed • when employees have been removed from their usual work activities due • where an adverse health surveillance result has been recorded • every five years as renewal of a notification where the use of the carcinogenic substance is continuous Prohibited and Notifiable Carcinogens Procedure Version 1.0 Effective 08/2011 Purchasing

Purchasing shall be done through Labstore only and can proceed when:
• written approval via the risk assessment process has been obtained from the Facility Manager, Head of School and the Manager, University Laboratories (or delegate). • written approval (i.e. the acknowledgement letter including the Workcover reference number) has been received from Workcover • Workcover reference number will need to be provided to suppliers. Record Keeping
A copy of Workcover acknowledgement letter shall be forwarded to:
• Manger, Occupational Health and Safety
• Manger, University Laboratories
• Head of School
• Facility Manager
The Notification Approval is valid for 5 years from the date of the Workcover
acknowledgement letter
. If the carcinogenic substance is in continual use
beyond this date, then the notification must be renewed following the same
procedure as outlined above.
3.5.1 School/Unit record keeping

The Head of School must retain the documents included in table 1.
Documentation must also be saved to the CSU document management
system and forwarded to the Faculty Office.
Type of record
Duration
The Prohibited and notifiable Application 30 years from when the application form and Workcover acknowledgement Risk Assessments for work with prohibited 30 years from the last activity and notifiable carcinogens Training and Induction records for work with prohibited and notifiable carcinogens Any air monitoring or health surveillance record (if applicable) Record of each worker who has been or is likely to be exposed to a prohibited and notifiable carcinogen (including DOB, full name and address) 3.5.2 Supplier Record Keeping
Suppliers have to keep invoices detailing supply of prohibited and notifiable
carcinogens for 5 years, including: Prohibited and Notifiable Carcinogens Procedure Version 1.0 Effective 08/2011 the name and address of person supplied the name and quantity of the substance supplied Health Surveillance
Carcinogenic substances for which health surveillance is mandatory are listed in Appendix 3, and all employees working with or exposed to any of these should seek further information from the Manager of Occupational Health and Safety.
3.6.1 Health surveillance should:

continue throughout the period of use of a scheduled carcinogenic substance. be repeated at the time of job transfer or termination of employment always follow professional advice on whether to continue health surveillance of employees after exposure to a scheduled carcinogenic substance has ceased 3.6.2 Record keeping of health surveillance:

shall be in accordance with the CSU Privacy Management Plan, the Privacy Act 1988 and the Privacy and Personal Information Protection Act 1998 (NSW) include the employee's date of commencement and termination, date of birth and specify the periods of potential exposure to any scheduled carcinogenic substance include the employee's present and past job classification and area of work include the employee's previous employment records in relation to any chemical exposure and medical condition where available. Disposal
Disposal should be as per Risk Assessment and other relevant documents. For further information consult the Facility Manager and/or the Chemical Safety Committee. Use of prohibited and notifiable substances without approval
If prohibited and notifiable substances are being used in the laboratory without the required approvals: • Notify the Head of School, the Manager of University Laboratories and the Facility Manager Suspended all work Work can not resume until all approvals are in place 4.0 APPENDICES
Prohibited and Notifiable Carcinogens Procedure Version 1.0 Effective 08/2011 Notifiable carcinogenics Prohibited carcinogenics Notifiable and Prohibited Carcinogens for which Health Surveillance is required. 5.0 Table of amendments
Short description of amendment
Adj as per K Munn Amendments K Kent Amendments L Hawkins Prohibited and Notifiable Carcinogens Procedure Version 1.0 Effective 08/2011 Appendix 1 - Prohibited carcinogens (clause 158 of the OHS regulation)
2-Acetylaminofluorene Aflatoxins – except in foods where specifically permitted under the Food Act 1989
4-Aminodiphenyl
Amosite (brown asbestos) – except for removal, disposal, maintenance, encapsulation and enclosure purposes, and
situations where amosite occurs naturally and is not used for
any new application
Benzidine and its salts
(including benzidine dihydrochloride ) bis(Chloromethyl) ether Chloromethyl methyl ether [ (technical grade which contains bis(chloromethyl) ether)
Chrysotile (white asbestos) – except when:
• used for the purpose of research or analysis
• or being removed or disposed of
• or being handled for storage or stored awaiting disposal
• or encountered during non-asbestos mining
• or comprising or included in an item being used for the
purpose of a historical or educational display. Crocidolite (blue asbestos) – except for removal, disposal, maintenance, encapsulation and enclosure purposes, and situations where crocidolite occurs naturally and is not used for any new application 4-Dimethylaminoazobenzene] 2-Naphthylamine and its salts For further information referring to the use of carcinogens other than those listed above, refer tosubstances. Prohibited and Notifiable Carcinogens Procedure Version 1.0 Effective 08/2011 Appendix 2 - notifiable carcinogens (from Workcover)
Benzene -– when used as a feedstock containing more than 50% of benzene by volume
Cyclophosphamide (cytotoxic drug) -– when used in preparations
for therapeutic use in hospitals and oncological treatment
facilities, and in manufacturing operations
3,3′-Dichlorobenzidine and its salts (including 3,3′ -
Dichlorobenzidine dihydrochloride) Diethyl sulphate Dimethyl sulphate Ethylene dibromide– when used as a fumigant 4,4′-Methylene bis(2-chloroaniline) - MOCA o-Toluidine hydrochloride Vinyl chloride monomer Prohibited and Notifiable Carcinogens Procedure Version 1.0 Effective 08/2011 Appendix 3 - Notifiable and Prohibited Carcinogens for which Health
Surveillance is required
(From OHS 2001 Regulations clause 165)
Hazardous substance
Type of health surveillance
Occupational and medical history Demographic data Records of personal exposure Arsenic (inorganic) Demographic, medical and occupational history Exposure record Physical examination with emphasis on the peripheral nervous system and skin Urinary inorganic arsenic Occupational and demographic data Medical interview Records of personal exposure Occupational and medical history Demographic data Exposure record Baseline blood sample for haematological profile Demographic, medical and occupational history Exposure record Physical examination with emphasis on the respiratory system Standard respiratory questionnaire to be completed Standard respiratory function tests including for example, FEV1, FVC and FEV1/FVC Urinary cadmium and β2-microglobulin Chromium (inorganic) Demographic, occupational and medical history Physical examination with emphasis on the respiratory system and skin Weekly skin inspection of hands and forearms by a competent person Demographic, occupational and medical history Health advice, including recognition of photosensitivity and skin changes Physical examination with emphasis on the neurological system and skin, noting any abnormal lesions and evidence of skin sensitisation Exposure record, including photosensitivity Crystalline Silica Completion of a standardised respiratory questionnaire Standard respiratory function test, such as FEV1, FVC and FEV1/FVC Chest X-ray, full size PA view Occupational and medical history Completion of a standardised respiratory questionnaire Physical examination of the respiratory system and skin Standard respiratory function test, such as FEV1, FVC and FEV1/FVC Prohibited and Notifiable Carcinogens Procedure Version 1.0 Effective 08/2011 Lead (inorganic) Medical and occupational history Physical examination Mercury (inorganic) Demographic, medical and occupational history Physical examination with emphasis on dermatological, gastrointestinal, neurological and renal systems Urinary inorganic mercury MOCA (4,4-Methylenebis (2- Urinary total MOCA Dipstick analysis of urine for haematuria Urine cytology Organophosphate pesticides Occupational and medical history Physical examination Baseline estimation of red cell and plasma cholinesterase activity levels by the Ellman or equivalent method Estimation of red cell and plasma cholinesterase activity towards the end of the working day Pentachlorophenol (PCP) Demographic, occupational and medical history Physical examination with emphasis on the skin, noting any abnormal lesions or effects of irritancy Urinary total pentachlorophenol Dipstick urinalysis for haematuria and proteinuria Records of personal exposure Polycyclic aromatic Exposure record, including photochemical skin burns Demographic, medical and occupational history Physical examination Demographic, medical and occupational history Physical examination Urinary thallium Occupational and demographic data Record of personal exposure Prohibited and Notifiable Carcinogens Procedure Version 1.0 Effective 08/2011

Source: https://science.csu.edu.au/__data/assets/pdf_file/0004/151663/Prohibited-and-Notifiable-Carcinogens-Procedure_KKIS.pdf

Pii: s0090-4295(97)00700-0

USE OF INTRALESIONAL VERAPAMIL TO DISSOLVE PEYRONIE'S DISEASE PLAQUE: A LONG-TERM SINGLE-BLIND STUDY JAMIL REHMAN, ALEXANDRU BENET, AND ARNOLD MELMAN Objectives. Multiple conservative therapies for the treatment of Peyronie's disease have been offered withvariable and poor response rates. Calcium channel blockers have been shown in vitro and in vivo to inhibitsecretion and synthesis of extracellular matrix, including collagen, glycosaminoglycans, and fibronectin, aswell as causing increased collagenase and anti transforming growth factor-beta activity. Calcium antagonists,including verapamil, are effective in stimulating the remodeling and degradation of extracellular matrix intissue by altering the metabolic pathways of fibroblasts. Recently, a pilot study (1994) showed preliminarypromising results in treating plaque caused by Peyronie's disease. This randomized single-blind placebo-based study (1994 to 1996) was undertaken to confirm the hypothesis.Methods. In this randomized single-blind study, 14 patients completed the study and were divided into twogroups: the verapamil treatment group (n 5 7) or the control saline group (n 5 7). Verapamil or saline was

Nuclear general employee training

NUCLEAR GENERATION GROUP STUDY GUIDE Rev. 24 - July 2001 This student guidebook is provided as a ready reference only and will cover MOST of the material presented in the Nuclear General Employee Training class. It is expected that students remain familiar with ALL N-GET material to work